glp-1 agonist gastroparesis receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal A 32-year-old man developed gastroparesis
Description
Minerva Endocrinol
It works within our body's natural systems rather than overriding them, and so, combined with lifestyle which we should always have lifestyle in there it could be a great natural alternative to at least start with, if you are considering those drugs
Mol Cell 2020;80:485500.PubMed 44
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies
For injectable medications, some patients find evening injections reduce daytime nausea
Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials
